Equities Analysts Offer Predictions for Zura Bio Q1 Earnings

Zura Bio Limited (NASDAQ:ZURA) – Equities research analysts at HC Wainwright cut their Q1 2025 EPS estimates for shares of Zura Bio in a research report issued to clients and investors on Thursday, April 3rd. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of ($0.21) for the quarter, down from their prior estimate of ($0.20). HC Wainwright has a “Neutral” rating and a $3.00 price objective on the stock. The consensus estimate for Zura Bio’s current full-year earnings is ($0.65) per share. HC Wainwright also issued estimates for Zura Bio’s Q2 2025 earnings at ($0.21) EPS, Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.21) EPS and FY2025 earnings at ($0.85) EPS.

Other analysts have also issued reports about the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zura Bio in a report on Wednesday, December 11th. Oppenheimer reaffirmed an “outperform” rating and set a $19.00 price objective (down previously from $20.00) on shares of Zura Bio in a research note on Wednesday, March 26th. Guggenheim reiterated a “buy” rating and issued a $15.00 target price on shares of Zura Bio in a research note on Wednesday, March 26th. Finally, Chardan Capital lowered their price target on shares of Zura Bio from $12.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, March 26th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Zura Bio presently has a consensus rating of “Buy” and a consensus target price of $14.67.

Zura Bio Stock Performance

NASDAQ ZURA opened at $1.03 on Monday. The firm has a market capitalization of $67.25 million, a P/E ratio of -1.94 and a beta of 0.08. The stock has a 50-day simple moving average of $1.40 and a two-hundred day simple moving average of $2.63. Zura Bio has a fifty-two week low of $0.97 and a fifty-two week high of $6.35.

Zura Bio (NASDAQ:ZURA) last posted its earnings results on Tuesday, March 25th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.09. The business had revenue of $0.00 million for the quarter.

Institutional Investors Weigh In On Zura Bio

A number of institutional investors have recently added to or reduced their stakes in ZURA. American Century Companies Inc. purchased a new position in Zura Bio during the fourth quarter valued at $27,000. Prudential Financial Inc. purchased a new position in Zura Bio in the 4th quarter valued at about $28,000. Two Sigma Advisers LP acquired a new stake in Zura Bio in the 4th quarter worth about $32,000. ProShare Advisors LLC purchased a new stake in Zura Bio during the 4th quarter worth approximately $35,000. Finally, XTX Topco Ltd acquired a new position in shares of Zura Bio during the fourth quarter valued at approximately $44,000. Institutional investors and hedge funds own 61.14% of the company’s stock.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.